RNA trans-splicing to rescue β-catenin: A novel approach for treating CTNNB1-Haploinsufficiency disorder

Loss-of-function mutations in the CTNNB1 gene cause β-catenin deficiency, resulting in CTNNB1 syndrome, a rare neurodevelopmental disorder characterized by motor and cognitive impairments. Given the wide variety of mutations across CTNNB1 and its dosage sensitivity, a mutation-independent therapeutic approach that preserves endogenous gene regulation is critically needed. This study introduces spliceosome-mediated RNA trans-splicing as a novel approach to restore β-catenin production. Pre-trans-splicing RNA molecules (PTMs) targeting CTNNB1 introns 2, 5, and 6 were designed and evaluated using a split yellow fluorescent protein reporter system. Rationally designed short antisense RNAs, which mask splicing regulatory elements, significantly enhanced PTM-mediated trans-splicing at both mRNA and protein levels. Additionally, introducing a self-cleaving ribozyme at the PTM’s 5′ end further improved trans-splicing efficiency, likely due to increased nuclear retention. CMV promoter-driven PTM expression yielded the highest efficiency. Importantly, successful trans-splicing of the endogenous CTNNB1 transcript confirmed the physiological relevance of this strategy. This study is the first to apply and optimize spliceosome-mediated RNA trans-splicing (SMaRT) for CTNNB1 mRNA correction, providing a promising, mutation-agnostic approach for treating CTNNB1 syndrome.

• Publication year

  2025

• Venue

  Molecular Therapy: Nucleic Acids

• Publication date

  2025-08-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.omtn.2025.102680PMID 40896583PMCID 12398835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paving the way toward treatment solutions for CTNNB1 syndrome: a patient organization perspective

  2025cited by this paper
• Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing

  2024cited by this paper
• Specific features of ß-catenin-mutated hepatocellular carcinomas

  2024cited by this paper
• Programmable RNA writing with trans-splicing

  2024cited by this paper
• Programmable multi-kilobase RNA editing using CRISPR-mediated trans-splicing

  2023cited by this paper
• mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy

  2023cited by this paper
• Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants.

  2022cited by this paper
• Expression pattern and clinical significance of β-catenin gene and protein in patients with primary malignant and benign bone tumors

  2022cited by this paper
• 5′RNA Trans-Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa

  2022cited by this paper
• Correlation between Phenotype and Genotype in CTNNB1 Syndrome: A Systematic Review of the Literature

  2022cited by this paper
• Therapeutic applications of trans-splicing.

  2020cited by this paper
• A catalogue of new incidence estimates of monogenic neurodevelopmental disorders caused by de novo variants

  2020cited by this paper
• A de novo CTNNB1 Novel Splice Variant in an Adult Female with Severe Intellectual Disability

  2020cited by this paper
• Light-controlled twister ribozyme with single-molecule detection resolves RNA function in time and space

  2020cited by this paper
• Polyadenylation and nuclear export of mRNAs

  2019cited by this paper
• RNA Trans-Splicing Modulation via Antisense Molecule Interference

  2018cited by this paper
• RNA Structure Design Improves Activity and Specificity of trans-Splicing-Triggered Cell Death in a Suicide Gene Therapy Approach

  2018cited by this paper
• Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA

  2018cited by this paper
• Exon 3 mutations of CTNNB1 drive tumorigenesis: a review

  2017cited by this paper
• mRNA capping: biological functions and applications

  2016cited by this paper
• mRNA trans‐splicing in gene therapy for genetic diseases

  2016cited by this paper
• Repair of Rhodopsin mRNA by Spliceosome-Mediated RNA Trans-Splicing: A New Approach for Autosomal Dominant Retinitis Pigmentosa

  2015cited by this paper
• De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: expanding the mutational and clinical spectrum

  2014cited by this paper
• Dominant β-catenin mutations cause intellectual disability with recognizable syndromic features.

  2014cited by this paper
• Pol III Promoters to Express Small RNAs: Delineation of Transcription Initiation

  2014cited by this paper
• Cis-splicing and translation of the pre-trans-splicing molecule combine with efficiency in spliceosome-mediated RNA trans-splicing.

  2014cited by this paper
• Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches

  2013cited by this paper
• A Reporter-Based Screen to Identify Potent 3’ Trans-Splicing Molecules for Endogenous RNA Repair

  2013cited by this paper
• Spliceosome-mediated trans-splicing: the therapeutic cut and paste.

  2012cited by this paper
• Diagnostic exome sequencing in persons with severe intellectual disability.

  2012cited by this paper
• Two distinct catalytic strategies in the hepatitis δ virus ribozyme cleavage reaction.

  2011cited by this paper
• Exon Exchange Approach to Repair Duchenne Dystrophin Transcripts

  2010cited by this paper
• Trans-Splicing-Mediated Improvement in a Severe Mouse Model of Spinal Muscular Atrophy

  2010cited by this paper
• Chimeric Adeno-Associated Virus/Antisense U1 Small Nuclear RNA Effectively Rescues Dystrophin Synthesis and Muscle Function by Local Treatment of mdx Mice

  2006cited by this paper
• Base-stacking and base-pairing contributions into thermal stability of the DNA double helix

  2006cited by this paper
• Spliceosome-Mediated RNA Trans-Splicing with Recombinant Adeno-Associated Virus Partially Restores Cystic Fibrosis Transmembrane Conductance Regulator Function to Polarized Human Cystic Fibrosis Airway Epithelial Cells

  2005cited by this paper
• A new vector, based on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs in mammalian cells.

  2004cited by this paper
• Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency

  2004cited by this paper
• 5' exon replacement and repair by spliceosome-mediated RNA trans-splicing.

  2003cited by this paper
• Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing Signals

  2003cited by this paper
• Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Δ48-50 DMD cells

  2002cited by this paper
• Partial correction of endogenous ΔF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing

  2002cited by this paper
• Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing.

  2001cited by this paper
• Spliceosome-mediated RNA trans-splicing as a tool for gene therapy

  1999cited by this paper
• Expression of small, therapeutic RNAs in human cell nuclei

  1997cited by this paper
• Gamma-monomethyl phosphate: a cap structure in spliceosomal U6 small nuclear RNA.

  1989cited by this paper

• No citing papers are available for this paper.